Sunitinib in Pancreatic Neuroendocrine Tumors: Updated Progression-Free Survival and Final Overall Survival From a Phase III Randomized Study.

Authors :: UCL - SSS/IREC - Institut de recherche expérimentale et clinique
UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie
UCL - (SLuc) Service de gastro-entérologie
Faivre, S
Niccoli, P
Castellano, D
Valle, J W
Hammel, P
Raoul, J-L
Vinik, A
Van Cutsem, E
Bang, Y-J
Lee, S-H
Borbath, Ivan
Lombard-Bohas, C
Metrakos, P
Smith, D
Chen, J-S
Ruszniewski, P
Seitz, J-F
Patyna, S
Lu, D R
Ishak, K J
Raymond, E
UCL - SSS/IREC - Institut de recherche expérimentale et clinique
UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie
UCL - (SLuc) Service de gastro-entérologie
Faivre, S
Niccoli, P
Castellano, D
Valle, J W
Hammel, P
Raoul, J-L
Vinik, A
Van Cutsem, E
Bang, Y-J
Lee, S-H
Borbath, Ivan
Lombard-Bohas, C
Metrakos, P
Smith, D
Chen, J-S
Ruszniewski, P
Seitz, J-F
Patyna, S
Lu, D R
Ishak, K J
Raymond, E
Source :: Annals of Oncology, Vol. epub head of print, no.epub ahead of print, p. mdw561 (2016)
Publication Year :: 2016
Abstract: In a phase III trial in patients with advanced, well-differentiated, progressive pancreatic neuroendocrine tumors, sunitinib 37.5 mg/day improved investigator-assessed progression-free survival (PFS) versus placebo (11.4 vs. 5.5 months; HR, 0.42; P < 0.001). Here, we present PFS using retrospective blinded independent central review (BICR) and final median overall survival (OS), including an assessment highlighting the impact of patient crossover from placebo to sunitinib.

Database :: OAIster
Journal :: Annals of Oncology, Vol. epub head of print, no.epub ahead of print, p. mdw561 (2016)
Notes :: Ndonga
Publication Type :: Electronic Resource
Accession number :: edsoai.on1130465012
Document Type :: Electronic Resource

Tools